Astellas Pharma Inc Stock (OTCMKTS:ALPMY)


$ 15.75
Today's Range
$ 15.32 - $ 15.85
52-Week Range
$ 14.55 - $ 18.18
Market Cap
$ 29.63B

About Astellas Pharma Inc (OTCMKTS:ALPMY)

(OTCMKTS:ALPMY) Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; and research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Show more

ALPMY Stock Price

Statistics Highlights (OTCMKTS:ALPMY)

Shares Outstanding 1.83B Beta 0.64
Public Float 1.80B P/E Ratio 32.28
% Short of Float - Dividend (Yield) 50.00 (0.03%)
Held by Insiders - Ex-Dividend Date Mar 29, 2022
Held by Institutions 0.07% IPO Date -

ALPMY Financial Summary

Mar 22 Mar 21 Mar 20
Revenue $1.30T $1.25T $1.30T
EBITDA $241.52B $220.31B $314.75B
Net Income $124.09B $120.59B $195.41B
Total Assets $2.33T $2.27T $2.32T
Total Cash $315.99B $326.13B $318.39B
Total Debt $ $ $
Mar 22 Dec 21 Sep 21
Revenue $303.87B $340.63B $325.52B
EBITDA $11.24B $101.14B $73.45B
Net Income $-8.41B $60.88B $40.92B
Total Assets $2.33T $2.36T $2.26T
Total Cash $315.99B $350.21B $318.30B
Total Debt $ $ $


What is today's stock price of Astellas Pharma Inc (OTCMKTS:ALPMY)?

  • The current stock price of Astellas Pharma Inc (OTCMKTS:ALPMY) is $15.75.
  • Today ALPMY stock price opened at $15.32 after previous close of $16.14.
  • During the day, Astellas Pharma Inc stock quote has varied from a low of $15.32 to a high of $15.85.

What is Astellas Pharma Inc's 52-week change?

  • ALPMY 52-week high stock quote is $18.18, which is 15.40% above the current share price.
  • The Astellas Pharma Inc (OTCMKTS:ALPMY) 52-week low stock price is $14.55, which is 7.60% below the current share price.
  • Astellas Pharma Inc share price volatility (52-week beta) is 0.64.

Astellas Pharma Inc (OTCMKTS:ALPMY) FAQ

How Much is Astellas pharma inc Worth?

Astellas pharma inc's worth today based on market capitalisation is $29.63B

How much dividend does Astellas pharma inc Pay?

The current annualized dividend payout for ALPMY stock is $0.41, the dividend yield is 2.56% and the payout ratio is 32.05%.
View More Details on Astellas pharma inc's "Dividend" Section

What is Astellas pharma inc’s Price to Earning (PE) ratio?

Astellas pharma inc has a Price to Earning (P/E) ratio of 32.28. ALPMY stock also has a Price to Sales (P/S) ratio of 0.02, a Price to Book of 2.76 and Price/Earnings to Growth (PEG) of 0.00.

What is the Astellas pharma inc's ticker?

Astellas pharma inc trades on the OTC Markets stock market in USA under the ticker symbol "ALPMY". Astellas pharma inc’s stock symbol can also be displayed as "OTCMKTS:ALPMY".

Who are the owners of Astellas pharma inc?

Astellas pharma inc (OTCMKTS:ALPMY) is owned by 0.07% institutional shareholders and by 0.00% insiders. The rest is owned by the public.
Explore More Details on Astellas pharma inc's “Ownership” Section

Who are the key executives of Astellas pharma inc (ALPMY)?

Astellas pharma inc's key executive team includes the following managers:

  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Representative Director (1960)
  • Mr. Naoki Okamura BSc, Exec. VP, Chief Strategy Officer & Representative Director (NA)
  • Minoru Kikuoka, CFO & Sr. Managing Exec. Officer (NA)
  • Nobue Yasuda, Gen. Mang. of Fin. & Accounting Department (NA)
  • Mr. Yoshitsugu Shitaka Ph.D., Chief Scientific Officer & Sr. Managing Exec. Officer (NA)
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec. (NA)
  • Ms. Catherine B. Levitt, Gen. Counsel (NA)
  • Mr. Stig Ogata, VP of Corp. Communications (NA)
  • Ms. Collette Taylor, Sr. VP of HR (1963)
  • Chihiro Yokota, Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel. (NA)

What is Astellas pharma inc’s Sector & Industry Classification?

Astellas pharma inc (OTCMKTS:ALPMY) is classified under the "Healthcare" sector and under the "Drug Manufacturers-General" industry.

How many employees work for Astellas pharma inc?

Currently the number of employees working for Astellas pharma inc is 0.

Where are Astellas pharma inc's Headquarters?

Astellas pharma inc (OTCMKTS:ALPMY) is headquartered in Japan.

What are Astellas pharma inc's Address and Phone Number?

Astellas pharma inc’s mailing address is 2-5-1, Nihonbashi-Honcho, Tokyo, Japan, 103-8411.
The company’s phone number is 81 3 3244 3000.

What is the official website for Astellas pharma inc?

Astellas pharma inc’s official website is